<DOC>
	<DOCNO>NCT01670812</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety fresh frozen plasma ( FFP ) , high dose methylprednisolone ( HDMP ) rituximab ultra-high risk chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Trial FFP+HDMP+Rituximab Ultra-high Risk Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Chronic lymphocytic leukemia remain incurable particularly ultra-high risk subgroup , prognosis patient still dismal . This phase III , multicenter perspective clinical trial combination fresh frozen plasma ( FFP ) , high dose methylprednisolone ( HDMP ) rituximab ultra-high risk chronic lymphocytic leukemiaThe . The main purpose study investigate efficacy safety combinated regimen subgroup CLL patient . All enrol patient follow treatment period one year . Interim final evaluation do cycle treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Aged 1880 year old . 2 . Diagnosis chronic lymphocytic leukemia . 3 . Active disease meeting least one International Workshop Chronic Lymphocytic Leukemia 2008 criterion require treatment . 4 . Ultrahigh risk CLL ( Meets least one follow criterion ) ( 1 ) ultra highrisk genetics ( 17p deletion and/or TP53 mutation ) ( 2 ) short PFS ( &lt; 24 month ) intense immunochemotherapy treatment ( i.e . FCR , FR , PCR , BR etc ) ( 3 ) fludarabinerefractory 5 . Understand voluntarily sign informed consent form , able adhere study visit schedule protocol requirement 1 . Severe allergic constitution asthma . 2 . Recent myocardial infarction hypotension . 3 . ECOG performance status ≤ 2 study entry . 4 . Active hepatitis B ( DNA &gt; 1×103/ml ) 5 . Severe uncontrolled diabetes mellitus . 6 . Severe uncontrolled hypertension ( BP &gt; 150/90 mmHg treatment ) . 7 . Active uncontrolled systematic infection need treatment antibiotic . 8 . Clinical symptom dysfunction central nervous system . 9 . Unstable severe gastrorrhagia peptic ulcer . 10 . Major surgery within three week . 11 . Any potential drug abuse , medical , psychological social condition may disturb investigation assessment . 12 . In condition investigator consider ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>ultra-high risk</keyword>
	<keyword>fresh frozen plasma</keyword>
	<keyword>methylprednisolone</keyword>
	<keyword>rituximab</keyword>
</DOC>